|
Canada-0-LABORATORIES 公司名錄
|
公司新聞:
- Alumis Reports Year End 2025 Financial Results and Highlights Recent . . .
Alumis will provide an update of the TYK2 franchise strategy for both programs in the second quarter of 2026, including a timing update for commencing A‑005’s Phase 2 trial
- Alumis (ALMS) Faces Binary Setup: Upcoming SLE Data Could Break the . . .
Alumis (ALMS) Faces Binary Setup: Upcoming SLE Data Could Break the TYK2 "Pipeline-in-a-Pill" Thesis The math is straightforward The company's burn rate for 2025 was $386 0 million The new cash, therefore, covers that burn and extends the runway significantly Management states the combined cash position will fund operations into Q4 2027 This provides a tangible timeline to the planned NDA
- Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for . . .
SOUTH SAN FRANCISCO, Calif , March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that results from its Phase 3 ONWARD program evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque
- Alumis Inc. (ALMS) Stock Price, News, Quote History - Yahoo Finance
Find the latest Alumis Inc (ALMS) stock quote, history, news and other vital information to help you with your stock trading and investing
- Alumis Reports Year End 2025 Financial Results and Highlights Recent . . .
Alumis is currently evaluating additional immune‑mediated disease indications for envudeucitinib beyond PsO and SLE, and for its A‑005 program in central nervous system (CNS) and peripheral diseases, under a unified TYK2 franchise development strategy
- Alumis Reports Year End 2025 Financial Results and Highlights Recent . . .
Alumis is currently evaluating additional immune‑mediated disease indications for envudeucitinib beyond PsO and SLE, and for its A‑005 program in central nervous system (CNS) and peripheral diseases, under a unified TYK2 franchise development strategy
- Alumis (ALMS) Stifel Virtual Immunology and Inflammation Forum summary
TYK2 class and competitive landscape TYK2 inhibition shows strong genetic and clinical rationale, with efficacy linked to high target inhibition; initial class skepticism due to underperforming early molecules Recent data from multiple next-gen TYK2 inhibitors, including ESK-001, demonstrate improved efficacy and safety profiles
- Alumis Reports Year End 2025 Financial Results and Highlights Recent . . .
Alumis is currently evaluating additional immune‑mediated disease indications for envudeucitinib beyond PsO and SLE, and for its A‑005 program in central nervous system (CNS) and peripheral diseases, under a unified TYK2 franchise development strategy
- Alumis Inc. publishes corporate presentation on precision-engineered . . .
Alumis Inc publishes corporate presentation on precision-engineered TYK2 inhibitors for immune-mediated diseases Reuters 19 03 13:19 Like Alumis Inc -0 16% Pre
- Alumis Inc. (ALMS) 8-K Earnings Release - Mar 2026
“Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib’s highly differentiated clinical profile,” said Martin Babler, President and Chief Executive Officer of Alumis
|
|